片頭痛治療薬市場：治療クラス別、治療タイプ別、投与経路別、流通別-2025-2030年の世界予測

片頭痛治療薬市場は、2023年に47億4,000万米ドルと評価され、2024年には54億8,000万米ドルに達すると予測され、CAGR 15.83％で成長し、2030年には132億6,000万米ドルに達すると予測されています。

片頭痛治療薬市場の対象範囲には、急性および慢性の片頭痛を治療するために開発された医薬品が含まれ、その用途は予防的治療から頓挫治療まで多岐にわたる。この市場を牽引しているのは、世界的に生産性と生活の質に影響を及ぼしている広範な神経障害に対処する必要性です。トリプタン系薬剤、CGRP阻害剤、市販薬などの処方薬がその適用範囲の大部分を占め、最終用途は医療現場、薬局、個々の患者に及んでいます。市場の成長は、片頭痛の有病率の増加、薬剤製剤の進歩、患者やヘルスケア専門家の意識の高まりに大きく影響されています。世界の高齢化とストレスレベルの上昇が需要をさらに押し上げ、市場関係者にこれらの人口動態に対応するソリューションを革新する機会を提供しています。特に、個別化医療と非侵襲的送達メカニズムの開発は、有利な道を提供します。しかし、高額な薬剤費、潜在的な副作用、厳しい規制当局の承認プロセスなどによる制約があり、市場参入と拡大の課題となっています。さらに、伝統的な治療法や非医療的な治療法の存在は、需要を減退させる可能性があります。とはいえ、生物学的製剤、バイオシミラー、デジタル・セラピューティック・ソリューションの探求は、個々の遺伝子プロファイルに合わせた精密医療アプローチに関する広範な研究と並んで、技術革新のための肥沃な土壌を提示しています。同市場は激しい競争を特徴としており、競争上の優位性を維持し、進化する消費者の期待に応えるためには、継続的な研究開発が必要となります。企業は、特にヘルスケア・インフラが拡大しつつある新興国において、新技術へのアクセスや未開拓市場の開拓を目的とした戦略的パートナーシップの形成に注力すべきです。さらに、新しい治療法や片頭痛の誘因の管理について患者を教育する啓発キャンペーンに投資することで、市場での存在感を高めることができます。全体として、規制の変化や技術の進歩に機敏に対応し続けることは、市場情勢の複雑な状況を乗り切り、成長の可能性を活用する上で極めて重要です。

市場力学：急速に進化する片頭痛治療薬市場の主要市場インサイトを公開

片頭痛治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 片頭痛の発生率の増加と新薬の発売
  • 女性人口の増加とタバコ消費量の増加
  • 電気神経刺激装置などのヘルスケア施設の進歩
• 市場抑制要因
  • 片頭痛治療薬に関連する副作用
• 市場機会
  • 片頭痛治療薬に対する支援的な償還政策
  • 製薬セクターにおける協力・提携プログラムの増加
• 市場の課題
  • 代替療法の利用可能性と規制上の課題

ポーターの5つの力：片頭痛治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：片頭痛治療薬市場における外部からの影響の把握

外部マクロ環境要因は、片頭痛治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析片頭痛治療薬市場における競合情勢の把握

片頭痛治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス片頭痛治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、片頭痛治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨片頭痛治療薬市場における成功への道筋を描く

片頭痛治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 片頭痛の発生率増加と新薬の発売
    • 女性人口の増加とタバコ消費量の増加
    • 電気神経刺激装置などのヘルスケア施設の進歩
  • 抑制要因
    • 片頭痛治療薬に関連する副作用
  • 機会
    • 片頭痛薬に対する補助的な償還ポリシー
    • 製薬分野における協力とパートナーシップのプログラムの増加
  • 課題
    • 代替療法の利用可能性と規制上の課題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 片頭痛治療薬市場治療クラス別

• 吐き気止め薬
  • クロルプロマジン
  • メトクロプラミド
  • プロクロルペラジン
• 血圧降下薬
  • Β遮断薬
  • カルシウムチャネル遮断薬
• 麦角
  • ジヒドロエルゴタミン
  • エルゴタミン
  • ラスミディタン
• オピオイド薬
  • オキシコンチン
  • パーコセット
  • ビコディン
• 鎮痛剤
  • アスピリン
  • イブプロフェン
• トリプタン
  • リザトリプタン
  • スマトリプタン

第7章 片頭痛治療薬市場治療の種類別

• 中止
• 予防

第8章 片頭痛治療薬市場：投与経路別

• 注射可能
• 鼻スプレー
• オーラル

第9章 片頭痛治療薬市場配布元

• 病院併設薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカの片頭痛治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の片頭痛治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの片頭痛治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Aegis Therapeutics, LLC
• Alder Biopharmaceuticals, Inc.
• Allergan Inc. by AbbVie Inc.
• Amgen, Inc.
• AstraZeneca Plc
• Biohaven, Ltd
• Eisai Co., Ltd.
• Eli Lilly and Company
• Endo International Plc
• GlaxoSmithKline Plc
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

• FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. MIGRAINE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MIGRAINE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. CANADA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 78. CANADA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 79. CANADA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 81. CANADA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 82. CANADA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 83. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 84. CANADA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 129. CHINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 130. CHINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 131. CHINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 132. CHINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 133. CHINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 134. CHINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 135. CHINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 136. CHINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. CHINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. CHINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 139. INDIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 140. INDIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 141. INDIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 142. INDIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 143. INDIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 144. INDIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 145. INDIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 146. INDIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. INDIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. INDIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 310. ITALY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 311. ITALY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 312. ITALY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 313. ITALY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 314. ITALY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 315. ITALY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 316. ITALY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 317. ITALY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 318. ITALY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 319. ITALY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 324. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 328. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 330. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 331. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 332. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 333. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 334. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 337. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 338. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 339. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 340. NORWAY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 341. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 342. NORWAY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 343. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
• TABLE 344. NORWAY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
• TABLE 345. NORWAY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
• TABLE 346. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
• TABLE 347. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 348. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 349. NORWAY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 350. POLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 351. POLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
• TABLE 352. POLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
• TABLE 353. POLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MIL

The Migraine Drugs Market was valued at USD 4.74 billion in 2023, expected to reach USD 5.48 billion in 2024, and is projected to grow at a CAGR of 15.83%, to USD 13.26 billion by 2030.

The scope of the migraine drugs market encompasses medications developed to treat acute and chronic migraines, with applications spanning preventive and abortive treatments. This market is driven by the necessity to address a widespread neurological disorder impacting productivity and quality of life globally. Prescription drugs such as triptans, CGRP inhibitors, and over-the-counter medications form a significant part of its application scope, while the end-use spans healthcare settings, pharmacies, and individual patients. The market's growth is majorly influenced by the increasing prevalence of migraines, advancements in drug formulations, and rising awareness amongst patients and healthcare professionals. An aging population and increased stress levels globally further bolster demand, presenting opportunities for market players to innovate solutions catering to these demographics. Notably, personalized medicine and the development of non-invasive delivery mechanisms offer lucrative avenues. However, the market faces limitations due to high drug costs, potential side effects, and stringent regulatory approval processes which pose challenges to market entry and expansion. Furthermore, the presence of traditional and non-medical treatment alternatives can dilute demand. Nevertheless, the exploration of biologic drugs, biosimilars, and digital therapeutic solutions presents fertile ground for innovation, alongside conducting extensive research on precision medicine approaches tailored to individual genetic profiles. The market is characterized by intense competition, necessitating continuous research and development to maintain competitive advantage and meet evolving consumer expectations. Companies should focus on forming strategic partnerships to access new technologies and explore untapped markets, particularly in emerging economies where healthcare infrastructure is expanding. Additionally, investing in awareness campaigns to educate patients about new treatments and managing migraine triggers can enhance market presence. Overall, staying agile and responsive to regulatory shifts and technological advancements will be critical in navigating the complex landscape of the migraine drugs market and harnessing growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Migraine Drugs Market

The Migraine Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of migraines and launch of new drugs
  • Rise in female population and increase in cigarette consumption
  • Advancements in healthcare facilities such as electrical nerve stimulation devices
• Market Restraints
  • Side effects associated with migraine drugs
• Market Opportunities
  • Supportive reimbursement policies for migraine medications
  • Increased programmes of collaboration and partnership in the pharmaceutical sector
• Market Challenges
  • Availability of alternative therapies and regulatory challenges

Porter's Five Forces: A Strategic Tool for Navigating the Migraine Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Migraine Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Migraine Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Migraine Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Migraine Drugs Market

A detailed market share analysis in the Migraine Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Migraine Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Migraine Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Migraine Drugs Market

A strategic analysis of the Migraine Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Migraine Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aegis Therapeutics, LLC, Alder Biopharmaceuticals, Inc., Allergan Inc. by AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Biohaven, Ltd, Eisai Co., Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Migraine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapeutic Class, market is studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan.
• Based on Treatment Type, market is studied across Abortive and Preventive.
• Based on Route of Administration, market is studied across Injectable, Nasal Spray, and Oral.
• Based on Distribution, market is studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of migraines and launch of new drugs
    • 5.1.1.2. Rise in female population and increase in cigarette consumption
    • 5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with migraine drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Supportive reimbursement policies for migraine medications
    • 5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative therapies and regulatory challenges
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Migraine Drugs Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. Anti-Nausea Drug
  • 6.2.1. Chlorpromazine
  • 6.2.2. Metoclopramide
  • 6.2.3. Prochlorperazine
• 6.3. Blood Pressure Lowering Medication
  • 6.3.1. Beta-Blocker
  • 6.3.2. Calcium Channel Blocker
• 6.4. Ergots
  • 6.4.1. Dihydroergotamines
  • 6.4.2. Ergotamine
  • 6.4.3. Lasmiditan
• 6.5. Opioid Medication
  • 6.5.1. OxyContin
  • 6.5.2. Percocet
  • 6.5.3. Vicodin
• 6.6. Pain Reliever
  • 6.6.1. Aspirin
  • 6.6.2. Ibuprofen
• 6.7. Triptans
  • 6.7.1. Rizatriptan
  • 6.7.2. Sumatriptan

7. Migraine Drugs Market, by Treatment Type

• 7.1. Introduction
• 7.2. Abortive
• 7.3. Preventive

8. Migraine Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Nasal Spray
• 8.4. Oral

9. Migraine Drugs Market, by Distribution

• 9.1. Introduction
• 9.2. Hospitals Based Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Migraine Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Migraine Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Migraine Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Aegis Therapeutics, LLC
• 3. Alder Biopharmaceuticals, Inc.
• 4. Allergan Inc. by AbbVie Inc.
• 5. Amgen, Inc.
• 6. AstraZeneca Plc
• 7. Biohaven, Ltd
• 8. Eisai Co., Ltd.
• 9. Eli Lilly and Company
• 10. Endo International Plc
• 11. GlaxoSmithKline Plc
• 12. H. Lundbeck A/S
• 13. Johnson & Johnson Services, Inc.
• 14. Merck & Co. Inc.
• 15. Pfizer Inc.
• 16. Sanofi SA
• 17. Teva Pharmaceuticals Industries Ltd